KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Non-Current Deferred Tax Liability: 2020-2024

Historic Non-Current Deferred Tax Liability for AbCellera Biologics (ABCL) over the last 5 years, with Dec 2024 value amounting to $10.1 million.

  • AbCellera Biologics' Non-Current Deferred Tax Liability fell 23.76% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year decrease of 23.76%. This contributed to the annual value of $10.1 million for FY2024, which is 86.98% down from last year.
  • Per AbCellera Biologics' latest filing, its Non-Current Deferred Tax Liability stood at $10.1 million for FY2024, which was down 86.98% from $77.2 million recorded in FY2023.
  • Over the past 5 years, AbCellera Biologics' Non-Current Deferred Tax Liability peaked at $77.2 million during FY2023, and registered a low of $10.1 million during FY2024.
  • For the 3-year period, AbCellera Biologics' Non-Current Deferred Tax Liability averaged around $49.7 million, with its median value being $61.9 million (2022).
  • In the last 5 years, AbCellera Biologics' Non-Current Deferred Tax Liability skyrocketed by 65.54% in 2022 and then slumped by 86.98% in 2024.
  • AbCellera Biologics' Non-Current Deferred Tax Liability (Yearly) stood at $26.2 million in 2020, then soared by 42.75% to $37.4 million in 2021, then spiked by 65.54% to $61.9 million in 2022, then grew by 24.65% to $77.2 million in 2023, then tumbled by 86.98% to $10.1 million in 2024.